Rep. Gilbert Ray Cisneros, Jr. Unloads Shares of AtriCure, Inc. (NASDAQ:ATRC)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of AtriCure, Inc. (NASDAQ:ATRC). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in AtriCure stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

AtriCure Stock Up 0.8%

NASDAQ ATRC opened at $57.30 on Thursday. The stock has a 50 day moving average price of $52.05 and a 200-day moving average price of $37.89. AtriCure, Inc. has a one year low of $25.36 and a one year high of $61.70. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market capitalization of $2.91 billion, a P/E ratio of 247.26 and a beta of 1.24.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the previous year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts predict that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity at AtriCure

In other AtriCure news, insider Salvatore Privitera sold 7,763 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50. Following the transaction, the insider owned 150,921 shares of the company’s stock, valued at approximately $7,923,352.50. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Justin J. Noznesky sold 6,182 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the completion of the sale, the insider owned 100,219 shares of the company’s stock, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 74,868 shares of company stock worth $3,317,897 over the last three months. Corporate insiders own 4.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ATRC. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. UBS Group dropped their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Stifel Nicolaus set a $65.00 price objective on shares of AtriCure in a research report on Thursday, September 17th. Freedom Capital downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Finally, Weiss Ratings upgraded shares of AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $54.10.

Institutional Trading of AtriCure

Hedge funds and other institutional investors have recently bought and sold shares of the business. Man Group plc bought a new stake in AtriCure during the 2nd quarter valued at about $684,000. Bank of America Corp DE boosted its holdings in shares of AtriCure by 13.7% in the first quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after purchasing an additional 92,830 shares during the period. WINTON GROUP Ltd purchased a new stake in shares of AtriCure in the second quarter valued at approximately $1,002,000. The Manufacturers Life Insurance Company bought a new position in AtriCure in the second quarter worth approximately $699,000. Finally, Jupiter Topco LLC bought a new position in AtriCure in the second quarter worth approximately $640,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About AtriCure

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.